FDA Approves Fleqsuvy, a Concentrated Baclofen Oral Suspension, for the Treatment of Spasticity in Patients with Multiple Sclerosis.

The article presents the discussion on FDA approving baclofen oral suspension for the treatment of individuals with spasticity from multiple sclerosis (MS) or individuals with other spinal cord diseases or injuries. Topics include Fleqsuvy allowing for the lowest volume prescribed for patients showing the important consideration for suffering from dysphagi; and Fleqsuvy not indicating in the treatment of skeletal muscle spasm resulting from rheumatic disorders.